Phospholipids and a phospholipid-rich diet alter the in vitro amyloid-beta peptide levels and amyloid-beta 42/40 ratios

Neuroscience Letters

Volumn 481, Issue 2, 2010, Pages 73-77

  Amtul, Zareen ^a   Uhrig, Markus ^a   Supino, Rosanna ^b   Beyreuther, Konrad ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Alzheimer's disease; A ; Cos 7 cells; Phospholipids; Secretase

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; GAMMA SECRETASE; PHOSPHOLIPID;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; CELL MEMBRANE; CELL STRAIN COS7; CONTROLLED STUDY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; SENILE PLAQUE;

EID: 77955278673     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2010.06.046     Document Type: Article

References (33)

1. 31P NMR profiles of Alzheimer's disease and multiple subcortical infarct dementia. Neurology 1989, 39:1423-1427.
2. 31P nuclear magnetic resonance studies of anoxia in aged rat brain. Eur. Neurol. 1984, 23:141-143.
3. Cuenod C.A., Kaplan D.B., Michot J.L., Jehenson P., Leroy-Willig A., Forette F., Syrota A., Boller F. Phospholipid abnormalities in early Alzheimer's disease. In vivo phosphorus 31 magnetic resonance spectroscopy. Arch. Neurol. 1995, 52:89-94.
4. Farooqui A.A., Horrocks L.A. Plasmalogens: workhorse lipids of membranes in normal and injured neurons and glia. Neuroscientist 2001, 7:232-245.
5. Grimm H.S., Beher D., Lichtenthaler S.F., Shearman M.S., Beyreuther K., Hartmann T. gamma-Secretase cleavage site specificity differs for intracellular and secretory amyloid beta. J. Biol. Chem. 2003, 278:13077-13085.
6. Grimm M.O., Grimm H.S., Patzold A.J., Zinser E.G., Halonen R., Duering M., Tschape J.A., De Strooper B., Muller U., Shen J., Hartmann T. Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin. Nat. Cell Biol. 2005, 7:1118-1123.
7. Guan Z., Wang Y., Cairns N.J., Lantos P.L., Dallner G., Sindelar P.J. Decrease and structural modifications of phosphatidylethanolamine plasmalogen in the brain with Alzheimer disease. J. Neuropathol. Exp. Neurol. 1999, 58:740-747.
8. Hashimoto M., Hossain S., Agdul H., Shido O. Docosahexaenoic acid-induced amelioration on impairment of memory learning in amyloid beta-infused rats relates to the decreases of amyloid beta and cholesterol levels in detergent-insoluble membrane fractions. Biochim. Biophys. Acta 2005, 1738:91-98.
9. Hashimoto M., Tanabe Y., Fujii Y., Kikuta T., Shibata H., Shido O. Chronic administration of docosahexaenoic acid ameliorates the impairment of spatial cognition learning ability in amyloid beta-infused rats. J. Nutr. 2005, 135:549-555.
10. Higgins J.P., Flicker L. Lecithin for dementia and cognitive impairment. Cochrane Database Syst. Rev. 2003, 3:CD001015.
11. Jalink K., Hordijk P.L., Moolenaar W.H. Growth factor-like effects of lysophosphatidic acid, a novel lipid mediator. Biochim. Biophys. Acta 1994, 1198:185-196.
12. Jensen M., Hartmann T., Engvall B., Wang R., Uljon S.N., Sennvik K., Naslund J., Muehlhauser F., Nordstedt C., Beyreuther K., Lannfelt L. Quantification of Alzheimer amyloid beta peptides ending at residues 40 and 42 by novel ELISA systems. Mol. Med. 2000, 6:291-302.
13. 31P MRS of PCA extracts of postmortem Alzheimer's disease brain. Neurobiol. Aging 1996, 17:349-357.
14. Lange Y., Swaisgood M.H., Ramos B.V., Steck T.L. Plasma membranes contain half the phospholipid and 90% of the cholesterol and sphingomyelin in cultured human fibroblasts. J. Biol. Chem. 1989, 264:3786-3793.
15. Lichtenthaler S.F., Beher D., Grimm H.S., Wang R., Shearman M.S., Masters C.L., Beyreuther K. The intramembrane cleavage site of the amyloid precursor protein depends on the length of its transmembrane domain. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:1365-1370.
16. Masters C.L., Simms G., Weinman N.A., Multhaup G., McDonald B.L., Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. U.S.A. 1985, 82:4245-4249.
17. Mattson M.P. Pathways towards and away from Alzheimer's disease. Nature 2004, 430:631-639.
18. McDaniel M.A., Maier S.F., Einstein G.O. " Brain-specific" nutrients: a memory cure?. Nutrition 2003, 19:957-975.
19. Miller D.L., Papayannopoulos I.A., Styles J., Bobin S.A., Lin Y.Y., Biemann K., Iqbal K. Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease. Arch. Biochem. Biophys. 1993, 301:41-52.
20. Moolenaar W.H. Lysophosphatidic acid signalling. Curr. Opin. Cell Biol. 1995, 7:203-210.
21. Nitsch R.M., Blusztajn J.K., Pittas A.G., Slack B.E., Growdon J.H., Wurtman R.J. Evidence for a membrane defect in Alzheimer disease brain. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:1671-1675.
22. Patil S., Chan C. Palmitic and stearic fatty acids induce Alzheimer-like hyperphosphorylation of tau in primary rat cortical neurons. Neurosci. Lett. 2005, 384:288-293.
23. Patil S., Sheng L., Masserang A., Chan C. Palmitic acid-treated astrocytes induce BACE1 upregulation and accumulation of C-terminal fragment of APP in primary cortical neurons. Neurosci. Lett. 2006, 406:55-59.
24. 31P nuclear magnetic resonance study of the brain in Alzheimer's disease. J. Neuropathol. Exp. Neurol. 1988, 47:235-248.
25. Pettegrew J.W., Panchalingam K., Hamilton R.L., McClure R.J. Brain membrane phospholipid alterations in Alzheimer's disease. Neurochem. Res. 2001, 26:771-782.
26. Pettegrew J.W., Panchalingam K., Klunk W.E., McClure R.J., Muenz L.R. Alterations of cerebral metabolism in probable Alzheimer's disease: a preliminary study. Neurobiol. Aging 1994, 15:117-132.
27. 31P nuclear magnetic resonance (NMR) spectroscopy of brain in aging and Alzheimer's disease. J. Neural Transm. Suppl. 1987, 24:261-268.
28. 31P magnetic resonance spectroscopy in Alzheimer's and Pick's disease. Neurobiol. Aging 1993, 14:85-92.
29. St George-Hyslop P.H. Piecing together Alzheimer's. Sci. Am. 2000, 283:76-83.
30. Szoka F., Papahadjopoulos D. Comparative properties and methods of preparation of lipid vesicles (liposomes). Annu. Rev. Biophys. Bioeng. 1980, 9:467-508.
31. +)-dependent ATPases. A probable mechanism of action. Biochim. Biophys. Acta 1981, 642:96-105.
32. --ATPase activity. Life Sci. 2002, 72:455-463.
33. Xiong H., Callaghan D., Jones A., Walker D.G., Lue L.F., Beach T.G., Sue L.I., Woulfe J., Xu H., Stanimirovic D.B., Zhang W. Cholesterol retention in Alzheimer's brain is responsible for high beta- and gamma-secretase activities and Abeta production. Neurobiol. Dis. 2008, 29:422-437.